Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Active:	Yes
Cancer Type:	Breast Cancer	NCT ID:	NCT06428396
Trial Phases:	Phase II	Protocol IDs:	6482-029 (primary) NCI-2025-00468 LITESPARK-029 MK-6482-029
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06428396

Summary

The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482)
plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's
choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human
epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast
cancer. There is no formal hypothesis testing in this study.

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.